Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

Add in stabilised disease ... who presented the data at WCLC. On safety, there was a case of interstitial lung disease (ILD), a side effect that has been seen with other ADCs using Daiichi ...